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Background: Polycystic ovary syndrome (PCOS) is a common endocrinopathy, associated with metabolic abnormalities.
Metabolic features of various phenotypes of this syndrome are still debatable. The aim of present study hence was to
evaluate the metabolic and hormonal features of PCOS phenotypes in comparison to a group of healthy control.
Methods: A total of 646 reproductive-aged women were randomly selected using the stratified, multistage probability
cluster sampling method. The subjects were divided into five phenotypes: A (oligo/anovulation + hyperandrogenism +
polycystic ovaries), B (oligo/anovulation + hyperandrogenism), C (hyperandrogenism + polycystic ovaries) and D (oligo/
anovulation + polycystic ovaries). Hormonal and metabolic profiles and the prevalence of metabolic syndrome among
these groups were compared using ANCOVA adjusted for age and body mass index.
Results: Among women with PCOS (n = 85), those of groups A and C had higher serum levels of insulin and homeostatic
model assessment for insulin resistance (HOMA-IR), compared to PCOS women of group D. Serum concentrations of
cholesterol, low density lipoprotein, triglycerides and glucose in group A were higher than in other phenotypes, whereas
the metabolic syndrome was more prevalent among group B.
Conclusions: Women who had all three components of the syndrome showed the highest level of metabolic disturbances
indicating that metabolic screening of the severest phenotype of PCOS may be necessary.
Keywords: PCOS, Metabolic disorders, Metabolic syndrome, PhenotypeBackground
Polycystic ovary syndrome (PCOS) is one of the most com-
mon, complex and heterogeneous endocrine disorders
[1-4] affecting 6-10% of women of fertile age [5,6]. Al-
though the etiology of PCOS is still unclear, genetic and
environmental factors have been considered as possible
contributors [1,3,7]. PCOS is complicated mainly with
chronic anovulation (AnOvu), hyperandogenism (HA) and
polycystic ovary manifestation (PCO) on ultrasound exam-
ination [2,3,8,9]; it is also associated with metabolic disor-
ders such as obesity, dyslipidemia, inflammation laboratory
findings, high blood pressure, insulin resistance (IR) and
metabolic syndrome (MetS) [2,3,7,10], all of which lead to
cardiovascular diseases [11-13].* Correspondence: hrashidi@ajums.ac.ir
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article, unless otherwise stated.IR is strongly linked to PCOS [10] and hypernandrogenism
[14] and along with other hormonal irregularities has
been reported to be higher among obese PCOS women
than non-obese ones [1,3,15-17]; however its cause and
effect relationship has not been clarified [18]. In con-
trast, IR is usually associated with MetS, although this
higher prevalence of MetS has not always been reported
in all studies conducted in PCOS women [16]. It seems
that beside geographical and ethnical/racial variations
[7,16,17], the association between PCOS and MetS is
highly dependent on cut-offs defined for each of MetS
components [19], PCOS criteria, type of study and PCOS
phenotypes [18]. There are a limited number of studies on
the metabolic aspects of various PCOS phenotypes includ-
ing groups A (AnOvu +HA+ PCO), B (AnOvu +HA), C
(HA + PCO) and D (AnOvu + PCO) [3,18]. It is still
unclear that whether milder phenotypes have the same
metabolic and reproductive consequences as more severeed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Ramezani Tehrani et al. Reproductive Biology and Endocrinology 2014, 12:89 Page 2 of 6
http://www.rbej.com/content/12/1/89ones and whether we need to consider all of these
metabolic complications and use strict screening for
those with milder pictures [3,18,20]; some studies claim
that phenotype A exhibits the severest endocrine and
metabolic abnormalities [3,20,21], while phenotype D (the
normoandrogenic phenotype) shows less [7]. Contrary to
these, one study reported higher serum concentrations
of insulin in group B and an insignificant upward trend
of homeostatic model assessment of insulin resistance
(HOMA-IR) among groups B and D [2], a difference
which however disappeared after matching for age and
body mass index (BMI) [22]; hence it seems that higher
insulin and HOMA-IR could be related to a higher preva-
lence of obesity in these PCOS women, rather than its
phenotypes per se [20,21,23].
Due to a lack of adequate population based studies on
the metabolic aspects of the various PCOS phenotypes,
we aimed to compare the metabolic parameters of four
PCOS phenotypes to a group of non-PCOS controls in a




Ethical review board of the Research Institute for Endocrine
Sciences see Additional file 1 approved the study proposal
(initiation date of the study: 23/9/2010 and termination
date of the study: 10/3/2012 ) and informed consent was
obtained from all subjects see Additional file 2.
A stratified, multistage cluster with a probability in
proportion to size procedure was used for the sampling
method. The study design, recruitment process and data
collection have been described previously in detail else-
where [24]. In brief, a total of 646 women, aged 18-45 years
from urban areas of three cities of Khouzestan province,
including Ahvaz, Behbahan and Abadan, were randomly
selected. Menopausal women, those who had undergone
hysterectomy or bilateral oophorectomy and pregnant
ones were excluded (overall n = 21). To minimize the effect
of treatment bias, all other women, regardless of hormonal
usage such as insulin sensitizers and oral contraceptive
pills, were not excluded, but their hormonal and biochem-
ical parameters were not statistically analyzed.
A standard questionnaire was completed for eligible
women (n = 625). All participants underwent clinical ex-
aminations by trained staff of local medical universities/
schools and their body weight, height, waist (WC), hip
circumferences (HC) and blood pressure were measured
and documented. BMI was calculated as weight in kilo-
grams divided by height in meters squared (kg/m2). Acne
was scored based on its number, type and distribution [25].
An overnight fasting venous blood sample was obtained
from each subject on the second or third day of their spon-
taneous or progesterone induced menstrual cycles. All serawere stored at -80°C until the time of measurements. All
study subjects were invited for transvaginal or transabdom-
inal ultrasound scans of the ovaries, performed using either
the 3.5-MHz transabdominal or 5-MHz transvaginal trans-
ducer by an experienced sonographer in each province.
Ultrasound was performed as the same day as the blood
samples were collected.
Insulin (Ins) was measured by immunoenzymometric
assay (IEMA), (Mercodia, Uppsala, Sweden). Glucose (Glu),
Triglycerides (TG), Total Cholesterol (TC), Low Density
Lipoprotein (LDL) and High Density Lipoprotein (HDL)
were measured by enzymatic colorimetery, (Pars Amazon
Co. Tehran, Iran). HOMA-IR was calculated as fasting
insulin (mIU/L) * fasting glucose (mg/dl) /405.
The intra- and inter-assay coefficients of variation for
Ins were 0.9% and 1.1%, respectively; for Glu they were
1.3% and 2.9%, for TG 1.8% and 2.7%, for TC 0.8% and
2.8%, and for LDL 0.7% and 2.9%; and for HDL, these
values were 0.9% and 3.3%, respectively.
We defined PCOS in our study using the Rotterdam
(Rott) criteria, by which PCOS was defined as presence
of two or more of the following: oligo/amenorrhea,
clinical and/or biochemical hyperandrogenism, and polycys-
tic ovaries [26]. Women were subdivided into 5 groups
according to their manifestations: A) PCOS women who
had oligo/anovulation, hyperandrogenism and polycystic
ovaries, B) PCOS women with oligo/anovulation and
hyperandrogenism, C) PCOS women with hyperandrogenism
and polycystic ovaries, D) PCOS women with oligo/
anovulation and polycystic ovaries, and E) non-PCOS
women.
Hyperandrogenism (HA) was considered as clinical
(the presence of hirsutism scores ≥ 8, using the modi-
fied Ferriman-Gallwey scores/acne/androgenic alopecia
[24,25,27]) and/biochemical (circulating TT, FT, A4 and
DHEAS levels > the 95th percentile for the studied women,
who neither had clinical evidence of hyperandrogenism or
menstrual disturbances, nor were they taking any hormo-
nal medication) hyperandrogenism. Specifically, the upper
normal limits were total T =0.89 ng/ml, A4 = 2.9 ng/ml,
DHEAS =179 μg/dL and FAI =5.39. Oligo/anovulation
(AnOvu) was defined when there was amenorrhea, or
menstrual cycles longer than 35 days or less than 26 days
[28]. Polycystic ovaries (PCO) were identified on ultra-
sonography if 12 or more follicles with a 2–9 mm diam-
eter and/or increased ovarian volume were seen (10 cm3)
[24,29,30].
Metabolic syndrome was defined by the clinical diagnos-
tic criteria used for Iranian adult metabolic syndrome as
the presence of any three of five of the following character-
istics: (1) Waist circumference ≥ 95 cm; (2) Fasting TG ≥
150 mg/dl or drug treatment for elevated triglycerides; (3)
HDL cholesterol < 50 mg/dl or drug treatment for reduced
HDL-C; (4) Systolic blood pressure ≥130 or diastolic blood
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medication, and (5) Fasting glucose ≥ 100 mg/dl or treat-
ment with diabetes medication [31].
Statistical analysis
Continuous variables are presented as mean and standard
deviation or median and the 25th and 75th percentages,
following testing for normality, and categorical variables,
are expressed as percentages. Demographic and anthropo-
metric features between phenotypes are compared using
one way ANOVA and/or the Kruskal-Wallis Hand or
Pearson’s χ2 test, as appropriate. The association between
PCOS manifestations with hormonal and metabolic pa-
rameters are analyzed using ANCOVA, adjusted for age
and BMI. The association between MetS and phenotypical
groups adjusted for age and BMI are analyzed using logis-
tic regression model. Data analysis was performed using
the SPSS 15.0 PC package(SPSS Inc., Chicago, IL) and
statistical significance was set at P < 0.05.
Results
Of the 602 participants who completed the study, 85
women met the PCOS criteria; the most common pheno-
type among them was C (49.4%) i.e. they met two criteria
of PCOS including hyperandrogenism and polycystic ovar-
ies; group B (22.4%), D (15.3%), and A (12.9%) followed in
that order. Non-PCOS women were significantly older
than those with PCOS (33.9 ± 7.6 years vs 29.07 ± 7.7 years;
P < 0.001); however there were no significant differencesTable 1 Features of the participants, classified to 4 phenotyp
Phenotype A (n = 11) B (n
Variables AnOvu + HA + PCO AnO
Age (years) 25.6 ± 7.0 31.1
≤25 6 (54.5%) 7 (3
26-35 4 (36.4%) 5 (2
36-40 0 5 (2
≥41 1 (9.1%) 2 (1
Weight (Kg) 64.1 ± 11.9 66.2
Height (cm) 159.1 ± 4.4 158.
BMI (Kg/m2) 25.4 ± 5.0 26.4
Waist (cm) 76.1 ± 11.7 83.3
Hip (cm) 94.5 ± 11.6 98.8
WHR (cm) 0.80 ± 0.07 0.85
Systolic Blood Pressure (mmHg) 105.6 ± 12.5 106.
Diastolic Blood Pressure (mmHg) 65.0 ± 9.7 67.0
Hirsutism 8 (72.7%) 12 (
Acne 4 (36.4%) 7 (3
versus Normal, P<0.05.
† versus group A, P<0.05.
॥ versus group B, P<0.05.
‡ versus group C, P<0.05.in mean weight, height, BMI, WC, HC, waist to hip ratio
(WHR) between PCOS and non-PCOS participants. Table 1
shows the participants’ features stratified according to vari-
ous PCOS phenotypes and their non-PCOS counterparts.
PCOS women showed significantly higher serum levels
of total testosterone (TT) (0.28 ± 0.28 nmol/l; P < 0.001),
androstenedione (A4) (2.51 ± 1.62 ng/ml; P < 0.001), de-
hydroepiandrosterone sulfate (DHEAS) (166.49 ± 83.28 μg/
dl; P < 0.001), free androgen index (FAI) (2.32 ± 2.23; P <
0.001) and prolactin (PRL) (22.30 ± 14.43 ng/ml; P = 0.002)
versus non-PCOS ones. Table 2 shows hormonal and
metabolic profiles of the 4 PCOS phenotypes vs the non-
PCOS ones. The prevalence of MetS among PCOS women
was 7.1%, and19.53% in non-PCOS women. The preva-
lence of MetS among 4 PCOS phenotypes and non-PCOS
ones is presented in Figure 1.
Pearson’s χ2 test revealed that non-PCOS participants
indicated a significantly higher number of women with MetS,
compared to PCOS ones (P = 0.005). Regarding the pheno-
type groups, Pearson’s χ2 test showed that group C included
fewer number of women with MetS compared to those with-
out PCOS (P = 0.01). Multivariate logistic regression showed
that after adjustment for age and BMI, the prevalence of
MetS in group C was significantly lower than in the non-
PCOS women (OR= 0.22, 95% CI: 0.05, 0.99; P = 0.04).
Discussion
The present community-based study revealed that PCOS
phenotypes with hyperandrogenism (A, B and C) had theical groups and non-PCOS women
= 19) C (n = 42) D (n = 13) Normal
(n = 517)vu + HA HA + PCO AnOvu + PCO
± 7.8 30.3 ± 7.5 24.7 ± 6.8 33.9 ± 7.6
6.8%) 13 (31%) 8 (61.5%) 93(18%)
6.3%) 19 (45.2%) 4 (30.8%) 186(36%)
6.3%) 4 (9.5%)) 0 106(20.5%)
0.5%) 6 (14.3%) 1 (7.7%) 132(25.5%)
± 13.0 68.8 ± 11.3 57.7 ± 5.9 67.8 ± 13.1
2 ± 6.1 158.9 ± 5.2 156.3 ± 11.7 159.5 ± 6.2
± 4.8 27.2 ± 4.4 24.1 ± 5.5 26.6 ± 5.0
± 11.6 81.8 ± 8.9 74.5 ± 6.2 81.5 ± 10.7
± 11.9 100.48 ± 12.6 92.5 ± 6.5 100.4 ± 12.0
± 0.05 0.81 ± 0.10 0.82 ± 0.06 0.81 ± 0.09
4 ± 11.8 109.0 ± 11.1 107.9 ± †8.9 109.6 ± 12.9
± 10.4 70.4 ± 9.6 66.2 ± 9.3 68.9 ± 10.4
63.1%) 33 (78.5%) 0 †॥‡ 129(25%)
6.8%) 18 (42.9%) 4 (30.8%) 78(15.1%)
Table 2 The serum levels of the hormones and metabolic profile, classified to 4 phenotypical groups and in non-PCOS
women
Phenotype A (n = 11) B (n = 19) C (n = 42) D (n = 13) E (n = 517)
Variables AnOvu + HA + PCO AnOvu + HA HA + PCO AnOvu + PCO Normal
Testosterone (nmol/l) 0.4 ± 0.2 0.3 ± 0.4 0.2 ± 0.2 0.1 ± 0.1† 0.1 ± 0.2
Androstendione (ng/ml) 3.7 ± 1.9 3.2 ± 2.1 ‡ 2.0 ± 1.1 † 1.7 ± 0.7†‡ 1.4 ± 0.9
DHEAS (μg/dl) 205.7 ± 79.6 188.7 ± 93.4 ‡ 161.2 ± 81.5 116.7 ± 52.1†‡ 119.7 ± 73.3
SHBG (nmol/l) 50.1 ± 39.62 49.7 ± 31.5 44.6 ± 30.2 54.4 ± 29.3 54.8 ± 34.9
FAI 2.8 ± 1.7 2.8 ± 2.6 2.3 ± 2.3 1.0 ± 1.0 1.2 ± 1.5
LH (μU/ml) 7.5 ± 5.9 7.8 ± 7.7 6.7 ± 5.4 6.0 ± 4.6 6.3 ± 5.9
FSH (μU/ml) 7.5 ± 1.17 8.4 ± 3.5 10.8 ± 12.0 8.3 ± 1.8 11.6 ± 10.0
Prolactin (ng/ml) 22.8 ± 12.0 19.9 ± 16.3 22.8 ± 15.3 23.4 ± 10.7 19.6 ± 20.0
TSH (μU/ml) 2.4 ± 1.3 2.4 ± 1.5 3.2 ± 2.7 1.8 ± 0.6 2.8 ± 2.7
Free T4 (picomol/l 15.7 ± 1.9 16.0 ± 3.4 15.7 ± 2.0 17.0 ± 2.6 15.5 ± 2.2
Insulin (μU/ml) 13.1 ± 10.6 7.7 ± 2.8 10.5 ± 13.0 5.7 ± 3.8 †‡ 9.7 ± 9.4
HOMA-IR 3.1 ± 2.7 1.7 ± 0.7 2.1 ± 1.8 1.2 ± 0.9 †‡ 2.5 ± 3.0
Cholesterol (mg/dl) 167.5 ± 35.8 159.4 ± 24.2 165.4 ± 40.2 156.5 ± 34.4 169.5 ± 34.4
HDL (mg/dl) 47.2 ± 9.8 49.4 ± 13.3 49.1 ± 11.0 46.4 ± 12.0 46.4 ± 11.9
LDL (mg/dl) 97.0 ± 30.5 89.2 ± 24.1 96.9 ± 39.2 93.1 ± 29.0 98.8 ± 29.5
Triglycerides (mg/dl) 116.3 ± 57.3 103.5 ± 49.5 98.0 ± 38.6 83.9 ± 40.1 122.6 ± 80.5
Glucose (mg/dl) 95.5 ± 7.8 94.1 ± 22.0 90.3 ± 11.8 87.5 ± 7.6 100.3 ± 48.0
All analyses by ANCOVA adjusted for age and BMI.
versus group E, P < 0.05.
†versus group A, P < 0.05.
‡versus group C, P < 0.05.
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ance and metabolic syndrome. Furthermore the lipid and
glucose profiles of women with mild phenotype (D) were
better than the other PCOS groups, even non-PCOS ones.
Our findings also indicate that concurrency of the three
PCOS symptoms leads to increased severity of metabolic
disorders, especially hyperinsulinemia which may be re-
lated to more severe hyperanrogenemia.
Similar to our findings, a study conducted on 93 Polish
women with PCOS, showed elevated serum concentrations
of TT, Chol and LDL in the classic phenotype of PCOS i.e.Figure 1 Prevalence of MetS among participants, classified to 4
phenotypical groups and in non –PCOS women.group A [2]; other researchers have also reported the worst
disturbances [3,32]. In a study from Greece, IR was higher
among groups A and B, but had the lowest levels among
group C (HA + PCO), it was concluded that group C had
the lowest risk of cardiovascular diseases [20].
It is noteworthy that although PCOS women have shown
higher risk of cardiovascular diseases, yet hyperandrogenism
has not been proven to be the main contributor to fu-
ture cardiovascular diseases [6]; however PCOS has
been diagnosed in 55-80% of hyperandrogenic patients
[1]. As hyperinsulinemia can increase androgen secretion,
a PCOS characteristic, it is believed that hyperinsulinism
might contribute to PCOS development [32,33], and can
also lead to the development of Glu intolerance and type 2
diabetes [3,4]. necessitating more attention be given to
ethnic differences in insulin receptor action in PCOS [7].
Our findings of lower lipid- and Glu- profile-related
disorders in normoandrogenic patients (group D) were
consistent with the androgen excess and the PCOS society’s
claim that PCOS should initially be considered an androgen
excess disorder [20]. Group D without HA symptoms is
reported to have fewer metabolic abnormalities, lower BMI
and WC [7] findings in agreement with ours; in contrast a
study done in Italy on 220 PCOS women and 144 age and
BMI matched controls, found no association between IR
and HA compared to non-PCOS women [33]. Lower Glu
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muscles and decreased gluconeogenesis in the liver as a re-
sult of PCOS pathology [3].
Two studies documented an association between AnOvu
and metabolic disorders [10,32], although another reported
that the serum levels of TG and TC remain in the normal
range among PCOS women [6]. In the Rizzo et al study
(2009), the ovulatory PCOS phenotype showed lower TC,
TG, LDL and higher HDL levels, compared to anovulatory
ones [6]; findings similar to ours of an insignificant lower
prevalence of MetS in group C (ovulatory group); since in
our study more PCOS patients belonged to phenotype C,
this is a favorable finding. Phenotype B (AnOvu +HA)
showed the highest prevalence of MetS among 4 PCOS
groups; they were older and also had higher WHR, indicat-
ing higher incidence of androgenic obesity. The higher
prevalence of MetS among non-PCOS women is probably
due to older age and higher BMI, neither remaining signifi-
cant after adjustment for these two variables. These differ-
ences between groups is not be related to the selection bias
as aging decreases the prevalence of PCOS symptoms [12];
PCOS patients are hence more likely to be younger than
non-PCOS ones.
The slight differences between results of studies are prob-
ably due to genetic and environmental factors, in addition
to heterogeneity of PCOS phenotypes. Similar to our find-
ings, in another study conducted in Iran, the prevalence of
MetS in phenotype B was reported the highest. A study
conducted by Mehrabian et al has shown that PCO has
negative association with MetS [16] and the study of Amato
et al from Italy also showed that MetS is the least prevalent
in group C [33].
This study does have its strengths, such as using a
community-based sample instead of recruitment from
a referral centre. In addition, we used national cut points of
WC and HOMA-IR for the definition of abdominal obesity
and IR, respectively. To mention the limitations, since aging
decreases serum androgen levels and increases the preva-
lence of IR and MetS [20], a limitation of our study was
that women of non-PCOS group were significantly older
than PCOS ones; however we tried to eliminate this effect
by adjusting for age in the models. Furthermore the age dif-
ference between our 4 phenotypical groups was not signifi-
cant; therefore our comparative analysis may not have been
influenced by the age variation. Another potential limitation
that needs to be mentioned is that we used HOMA-IR as a
surrogate marker for assessing of IR; in spite of a good
correlation between HOMA-IR and gold standard clamp
methods [34,35] the assessment might be inaccurate.
Conclusions
In conclusion, our results indicate that, women with
hyperandrogenism exhibit the worst metabolic features.
As a result screening of phenotypes with hyperandrogenicsymptoms for detection of metabolic abnormalities is
highly recommended in the scope of PCOS. Further
longitudinal population based studies, with a prospective
risk assessment approach in larger sample sizes are needed
to analyze the long-term effects of metabolic profiles of
each phenotype.
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